S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
Log in
NASDAQ:ALEC

Alector Competitors

$16.25
-0.16 (-0.98 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$15.10
Now: $16.25
$16.33
50-Day Range
$15.29
MA: $18.31
$21.08
52-Week Range
$9.12
Now: $16.25
$34.89
Volume767,961 shs
Average Volume538,266 shs
Market Capitalization$1.29 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.08

Competitors

Alector (NASDAQ:ALEC) Vs. VIR, KOD, IOVA, CBPO, ALLO, and BEAM

Should you be buying ALEC stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Alector, including Vir Biotechnology (VIR), Kodiak Sciences (KOD), Iovance Biotherapeutics (IOVA), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), and Beam Therapeutics (BEAM).

Alector (NASDAQ:ALEC) and Vir Biotechnology (NASDAQ:VIR) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, institutional ownership, earnings, risk and profitability.

Risk & Volatility

Alector has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Comparatively, Vir Biotechnology has a beta of -0.99, indicating that its stock price is 199% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Alector and Vir Biotechnology, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alector00603.00
Vir Biotechnology20502.43

Alector currently has a consensus target price of $33.6667, indicating a potential upside of 107.18%. Vir Biotechnology has a consensus target price of $63.8571, indicating a potential upside of 60.97%. Given Alector's stronger consensus rating and higher probable upside, equities analysts clearly believe Alector is more favorable than Vir Biotechnology.

Profitability

This table compares Alector and Vir Biotechnology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alector-757.78%-53.86%-31.44%
Vir Biotechnology-339.61%-47.11%-39.44%

Valuation and Earnings

This table compares Alector and Vir Biotechnology's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alector$21.22 million60.94$-105,390,000.00($1.71)-9.50
Vir Biotechnology$8.09 million626.86$-174,680,000.00($5.76)-6.89

Alector has higher revenue and earnings than Vir Biotechnology. Alector is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

61.5% of Alector shares are owned by institutional investors. Comparatively, 54.5% of Vir Biotechnology shares are owned by institutional investors. 13.9% of Alector shares are owned by company insiders. Comparatively, 37.2% of Vir Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Alector beats Vir Biotechnology on 10 of the 14 factors compared between the two stocks.

Alector (NASDAQ:ALEC) and Kodiak Sciences (NASDAQ:KOD) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, institutional ownership, earnings, risk and profitability.

Risk & Volatility

Alector has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Comparatively, Kodiak Sciences has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Alector and Kodiak Sciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alector00603.00
Kodiak Sciences17302.18

Alector currently has a consensus target price of $33.6667, indicating a potential upside of 107.18%. Kodiak Sciences has a consensus target price of $129.1818, indicating a potential upside of 15.68%. Given Alector's stronger consensus rating and higher probable upside, equities analysts clearly believe Alector is more favorable than Kodiak Sciences.

Profitability

This table compares Alector and Kodiak Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alector-757.78%-53.86%-31.44%
Kodiak SciencesN/A-32.32%-23.86%

Valuation and Earnings

This table compares Alector and Kodiak Sciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alector$21.22 million60.94$-105,390,000.00($1.71)-9.50
Kodiak SciencesN/AN/A$-47,370,000.00($1.25)-89.34

Kodiak Sciences has lower revenue, but higher earnings than Alector. Kodiak Sciences is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

61.5% of Alector shares are owned by institutional investors. Comparatively, 82.3% of Kodiak Sciences shares are owned by institutional investors. 13.9% of Alector shares are owned by company insiders. Comparatively, 39.3% of Kodiak Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Kodiak Sciences beats Alector on 8 of the 13 factors compared between the two stocks.

Alector (NASDAQ:ALEC) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, institutional ownership, earnings, risk and profitability.

Institutional & Insider Ownership

61.5% of Alector shares are owned by institutional investors. Comparatively, 94.6% of Iovance Biotherapeutics shares are owned by institutional investors. 13.9% of Alector shares are owned by company insiders. Comparatively, 9.9% of Iovance Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Alector has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Comparatively, Iovance Biotherapeutics has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Alector and Iovance Biotherapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alector00603.00
Iovance Biotherapeutics02802.80

Alector currently has a consensus target price of $33.6667, indicating a potential upside of 107.18%. Iovance Biotherapeutics has a consensus target price of $50.10, indicating a potential upside of 57.70%. Given Alector's stronger consensus rating and higher probable upside, equities analysts clearly believe Alector is more favorable than Iovance Biotherapeutics.

Profitability

This table compares Alector and Iovance Biotherapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alector-757.78%-53.86%-31.44%
Iovance BiotherapeuticsN/A-50.64%-45.64%

Valuation and Earnings

This table compares Alector and Iovance Biotherapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alector$21.22 million60.94$-105,390,000.00($1.71)-9.50
Iovance BiotherapeuticsN/AN/A$-197,560,000.00($1.59)-19.98

Alector has higher revenue and earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Summary

Alector beats Iovance Biotherapeutics on 8 of the 13 factors compared between the two stocks.

Alector (NASDAQ:ALEC) and China Biologic Products (NASDAQ:CBPO) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Institutional and Insider Ownership

61.5% of Alector shares are held by institutional investors. Comparatively, 34.8% of China Biologic Products shares are held by institutional investors. 13.9% of Alector shares are held by company insiders. Comparatively, 2.7% of China Biologic Products shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Alector has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Comparatively, China Biologic Products has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for Alector and China Biologic Products, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alector00603.00
China Biologic Products0000N/A

Alector presently has a consensus target price of $33.6667, indicating a potential upside of 107.18%. Given Alector's higher probable upside, equities research analysts plainly believe Alector is more favorable than China Biologic Products.

Profitability

This table compares Alector and China Biologic Products' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alector-757.78%-53.86%-31.44%
China Biologic Products27.43%8.32%7.64%

Earnings & Valuation

This table compares Alector and China Biologic Products' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alector$21.22 million60.94$-105,390,000.00($1.71)-9.50
China Biologic Products$503.70 million9.23$138.81 million$4.2827.58

China Biologic Products has higher revenue and earnings than Alector. Alector is trading at a lower price-to-earnings ratio than China Biologic Products, indicating that it is currently the more affordable of the two stocks.

Summary

China Biologic Products beats Alector on 7 of the 13 factors compared between the two stocks.

Alector (NASDAQ:ALEC) and Allogene Therapeutics (NASDAQ:ALLO) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Institutional and Insider Ownership

61.5% of Alector shares are held by institutional investors. Comparatively, 59.9% of Allogene Therapeutics shares are held by institutional investors. 13.9% of Alector shares are held by company insiders. Comparatively, 31.3% of Allogene Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Alector has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Comparatively, Allogene Therapeutics has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for Alector and Allogene Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alector00603.00
Allogene Therapeutics031302.81

Alector presently has a consensus target price of $33.6667, indicating a potential upside of 107.18%. Allogene Therapeutics has a consensus target price of $52.0833, indicating a potential upside of 60.60%. Given Alector's stronger consensus rating and higher probable upside, equities research analysts plainly believe Alector is more favorable than Allogene Therapeutics.

Profitability

This table compares Alector and Allogene Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alector-757.78%-53.86%-31.44%
Allogene TherapeuticsN/A-27.59%-24.97%

Earnings & Valuation

This table compares Alector and Allogene Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alector$21.22 million60.94$-105,390,000.00($1.71)-9.50
Allogene TherapeuticsN/AN/A$-184,590,000.00($1.83)-17.72

Alector has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Summary

Alector beats Allogene Therapeutics on 7 of the 13 factors compared between the two stocks.

Alector (NASDAQ:ALEC) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Institutional and Insider Ownership

61.5% of Alector shares are held by institutional investors. Comparatively, 49.8% of Beam Therapeutics shares are held by institutional investors. 13.9% of Alector shares are held by company insiders. Comparatively, 0.7% of Beam Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations for Alector and Beam Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alector00603.00
Beam Therapeutics03302.50

Alector presently has a consensus target price of $33.6667, indicating a potential upside of 107.18%. Beam Therapeutics has a consensus target price of $96.00, indicating a potential upside of 30.63%. Given Alector's stronger consensus rating and higher probable upside, equities research analysts plainly believe Alector is more favorable than Beam Therapeutics.

Profitability

This table compares Alector and Beam Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alector-757.78%-53.86%-31.44%
Beam Therapeutics-529,075.00%-103.41%-48.05%

Earnings & Valuation

This table compares Alector and Beam Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alector$21.22 million60.94$-105,390,000.00($1.71)-9.50
Beam Therapeutics$20,000.00212,996.07$-78,330,000.00($14.05)-5.23

Beam Therapeutics has lower revenue, but higher earnings than Alector. Alector is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Alector beats Beam Therapeutics on 10 of the 13 factors compared between the two stocks.


Alector Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Vir Biotechnology logo
VIR
Vir Biotechnology
1.6$39.67-5.3%$5.07 billion$8.09 million-16.81Analyst Report
Gap Up
Kodiak Sciences logo
KOD
Kodiak Sciences
1.5$111.67-3.2%$5.00 billionN/A-48.13Earnings Announcement
Analyst Report
Analyst Revision
Iovance Biotherapeutics logo
IOVA
Iovance Biotherapeutics
1.7$31.77-7.6%$4.67 billionN/A-16.55Analyst Upgrade
High Trading Volume
China Biologic Products logo
CBPO
China Biologic Products
0.8$118.06-0.1%$4.65 billion$503.70 million32.98Upcoming Earnings
Increase in Short Interest
Allogene Therapeutics logo
ALLO
Allogene Therapeutics
1.3$32.43-2.0%$4.56 billionN/A-15.23
Beam Therapeutics logo
BEAM
Beam Therapeutics
1.3$73.49-14.0%$4.26 billion$20,000.00-5.23High Trading Volume
RLAY
Relay Therapeutics
1.8$39.99-3.5%$3.60 billionN/A0.00
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.8$69.30-7.8%$3.39 billionN/A-39.83Analyst Report
Revolution Medicines logo
RVMD
Revolution Medicines
1.6$42.45-1.7%$2.82 billion$50.04 million0.00Earnings Announcement
Analyst Report
NantKwest logo
NK
NantKwest
1.1$25.75-3.2%$2.81 billion$40,000.00-36.27Decrease in Short Interest
Gap Up
Editas Medicine logo
EDIT
Editas Medicine
1.4$40.36-6.9%$2.72 billion$20.53 million-23.20Analyst Report
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$61.01-12.9%$2.69 billion$125.57 million-35.68Earnings Announcement
Analyst Report
Gap Up
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$8.81-3.0%$2.47 billion$31.43 million-6.03Gap Up
AlloVir logo
ALVR
AlloVir
1.4$34.53-7.5%$2.25 billionN/A0.00Insider Selling
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
0.8$45.86-1.9%$2.04 billionN/A0.00
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$10.92-8.7%$1.94 billion$48.83 million-14.37
bluebird bio logo
BLUE
bluebird bio
1.8$27.94-5.0%$1.88 billion$44.67 million-2.54Analyst Report
Vericel logo
VCEL
Vericel
1.5$40.41-4.2%$1.86 billion$117.85 million-4,041,000.00Analyst Report
Analyst Revision
Scholar Rock logo
SRRK
Scholar Rock
1.3$50.60-1.7%$1.70 billion$20.49 million-21.00Upcoming Earnings
News Coverage
Gap Up
Ocugen logo
OCGN
Ocugen
1.1$8.97-16.6%$1.69 billionN/A-6.06Analyst Report
Unusual Options Activity
Gap Up
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.1$39.07-2.5%$1.68 billionN/A0.00
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.23-0.3%$1.61 billion$102.43 million-18.72Analyst Downgrade
Analyst Revision
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$71.65-16.2%$1.59 billionN/A-48.41Earnings Announcement
Analyst Upgrade
Analyst Revision
Translate Bio logo
TBIO
Translate Bio
1.4$21.29-0.8%$1.58 billion$7.80 million-19.90Upcoming Earnings
Analyst Revision
News Coverage
Replimune Group logo
REPL
Replimune Group
1.5$32.30-1.3%$1.50 billionN/A-18.25News Coverage
REGENXBIO logo
RGNX
REGENXBIO
1.8$39.21-2.4%$1.47 billion$35.23 million-15.81Earnings Announcement
Analyst Downgrade
Analyst Revision
FMTX
Forma Therapeutics
1.8$33.42-8.4%$1.38 billion$100.56 million0.00Decrease in Short Interest
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.6$15.89-0.4%$1.33 billionN/A-3.44Earnings Announcement
Analyst Upgrade
Analyst Revision
Immunovant logo
IMVT
Immunovant
1.8$13.08-7.0%$1.28 billionN/A-10.14Increase in Short Interest
PCVX
Vaxcyte
1.8$23.62-9.4%$1.20 billionN/A0.00Insider Selling
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$15.25-1.2%$1.11 billion$356.07 million7.47Analyst Report
Mesoblast logo
MESO
Mesoblast
1.4$9.18-0.3%$1.08 billion$32.16 million-10.43Earnings Announcement
Analyst Upgrade
Analyst Revision
Cortexyme logo
CRTX
Cortexyme
1.3$36.37-3.2%$1.07 billionN/A-15.15Earnings Announcement
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$10.96-3.1%$1.07 billion$250,000.00-8.63Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Inhibrx logo
INBX
Inhibrx
1.7$26.56-9.9%$1.00 billionN/A0.00
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$19.25-1.6%$903.15 million$69.89 million-4.59
Passage Bio logo
PASG
Passage Bio
1.9$19.43-2.7%$892.17 millionN/A0.00Earnings Announcement
Analyst Upgrade
News Coverage
Gap Down
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$23.40-7.7%$883.61 millionN/A0.00Earnings Announcement
Analyst Report
News Coverage
Gap Down
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$23.73-8.0%$857.03 millionN/A-3.92News Coverage
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.7$10.40-10.4%$844.29 millionN/A-4.86
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.54-12.1%$821.06 millionN/A0.00
Cellectis logo
CLLS
Cellectis
1.2$19.31-4.3%$820.41 million$22.99 million-10.27
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.5$24.06-6.9%$804.13 millionN/A-9.94
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.29-4.7%$783.28 million$42.74 million-225.44
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$5.01-4.8%$775.44 million$1.12 million-5.06Analyst Upgrade
Vaxart logo
VXRT
Vaxart
1.3$5.92-7.4%$697.18 million$9.86 million-10.03Analyst Report
Gap Up
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.86-7.3%$667.23 million$2.51 million-4.16Earnings Announcement
Analyst Report
Increase in Short Interest
Athira Pharma logo
ATHA
Athira Pharma
2.2$19.29-6.8%$626.64 millionN/A0.00Decrease in Short Interest
News Coverage
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.4$30.61-8.2%$622.00 millionN/A0.00Increase in Short Interest
Gap Down
Agenus logo
AGEN
Agenus
1.6$3.16-7.3%$600.87 million$150.05 million-2.90
This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.